Loading…
Loading…
See exactly how SIO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SIO and 80,000+ other tickers.
Under typical market conditions, this fund commits a minimum of 80% of its overall assets to fixed-income instruments designed to generate income. A core component of its portfolio strategy involves allocating at least 50% of its holdings to debt securities rated as investment-grade. Furthermore, it has the discretion to invest up to 50% of its portfolio in non-investment-grade debt. The fund's managers generally opt to sell a security if its yield-to-price relationship no longer sufficiently offsets its risk profile, or if a reallocation across sectors is deemed appropriate due to shifts in relative market value.
Two independent studies of ProSense® cryoablation in breast cancer were presented, one of which won the Highest Scoring Abstract Award in its category Hands-on ProSense® training featured during the SIO Mini Masterclass on Breast Cryoablation; the session was extremely well attended with presentations led by interventional oncology and breast cancer thought leaders FDA's decision on ProSense® market authorization for early-stage breast cancer expected Q1 2025 CAESAREA, Israel , Feb. 4, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation as one of the sponsors of the Breast Cryoablation Mini Masterclass held during the 2025 Society of Interventional Oncology (SIO) Annual Meeting in Las Vegas, which took place January 29 to February 3, 2025.
THE WOODLANDS, TX, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced its abstract has been accepted for poster presentation at the SIO 2025 Annual Scientific Meeting, being held January 30 – February 3, 2025 in Las Vegas, NV.
Touchstone Investments now has six actively managed ETFs. It seeks to bring its “distinctively active” mutual fund approach to meet advisors where they are focused.
Touchstone Investments announced the launch of its first of four new actively managed exchange traded funds. The Touchstone Strategic Income Opportunities ETF (NYSE Arca: SIO) trades on the New York Stock Exchange Arca.